当前位置:首页 - 行情中心 - 华兰生物(002007) - 财务分析 - 现金流量表

华兰生物

(002007)

  

流通市值:251.95亿  总市值:292.79亿
流通股本:15.74亿   总股本:18.29亿

现金流量表

报告期2024-12-312024-09-302024-06-302024-03-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金4,934,564,892.163,552,444,941.922,295,901,505.781,154,184,261.52
收到的税费返还10,763,868.93309,649.98309,649.98-
收到其他与经营活动有关的现金68,051,640.9554,326,821.0231,455,218.7818,577,278.79
经营活动现金流入的平衡项目0000
经营活动现金流入小计5,013,380,402.043,607,081,412.922,327,666,374.541,172,761,540.31
购买商品、接受劳务支付的现金1,655,884,984.831,553,707,874.46927,578,583.47530,413,604.37
支付给职工以及为职工支付的现金478,493,657.33337,389,345.7254,218,543.21144,152,580
支付的各项税费505,016,300.05342,011,232.97236,351,768.18145,759,781.62
支付其他与经营活动有关的现金1,314,640,297.95914,263,533.24588,181,263.98302,249,100.92
经营活动现金流出的平衡项目0000
经营活动现金流出小计3,954,035,240.163,147,371,986.372,006,330,158.841,122,575,066.91
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额1,059,345,161.88459,709,426.55321,336,215.750,186,473.4
二、投资活动产生的现金流量:
收回投资收到的现金23,636,287,582.5317,901,290,166.7511,738,687,058.782,071,994,637.44
取得投资收益收到的现金135,294,495.93141,920,968.1116,215,602.1150,526,012.48
处置固定资产、无形资产和其他长期资产收回的现金净额892,593.2769,072.52690,239.88441,207.88
处置子公司及其他营业单位收到的现金净额1,550,0001,550,0007,030.28-
投资活动现金流入的平衡项目0000
投资活动现金流入小计23,774,024,671.6618,045,530,207.3711,855,599,931.052,122,961,857.8
购建固定资产、无形资产和其他长期资产支付的现金255,428,449.3457,425,868.78260,388,845.16110,356,015.61
投资支付的现金23,428,157,926.6117,569,564,573.6110,424,087,847.622,076,586,208.78
支付其他与投资活动有关的现金362,323.91-362,323.91162,323.91
投资活动现金流出的平衡项目0000
投资活动现金流出小计23,683,948,699.8218,026,990,442.3910,684,839,016.692,187,104,548.3
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额90,075,971.8418,539,764.981,170,760,914.36-64,142,690.5
三、筹资活动产生的现金流量:
吸收投资收到的现金16,281,00016,281,00016,281,000-
取得借款收到的现金596,468,571.01300,000,000300,000,000200,000,000
筹资活动现金流入平衡项目0000
筹资活动现金流入小计612,749,571.01316,281,000316,281,000200,000,000
偿还债务支付的现金700,000,000250,000,000.01150,000,000.01-
分配股利、利润或偿付利息支付的现金585,446,171.58586,908,790.4582,717,423.226,280,940.31
其中:子公司支付给少数股东的股利、利润117,616,500117,009,000117,009,000-
支付其他与筹资活动有关的现金107,736,520.27107,167,606.3939,127,951.38380,753.88
筹资活动现金流出平衡项目0000
筹资活动现金流出小计1,393,182,691.85944,076,396.8771,845,374.616,661,694.19
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额-780,433,120.84-627,795,396.8-455,564,374.61193,338,305.81
四、汇率变动对现金及现金等价物的影响-52,406.71-45,954.89-97,151-99,053.99
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额368,935,606.17-149,592,160.161,036,435,604.45179,283,034.72
加:期初现金及现金等价物余额989,324,615.51989,324,615.51989,324,615.51989,324,615.51
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额1,358,260,221.68839,732,455.352,025,760,219.961,168,607,650.23
补充资料:
净利润1,155,469,792.25-448,775,270.53-
资产减值准备74,225,065.72---
固定资产和投资性房地产折旧248,723,026.77-122,405,583.04-
其中:固定资产折旧、油气资产折耗、生产性生物资产折旧248,723,026.77-122,405,583.04-
无形资产摊销11,732,164.68-5,731,565.79-
长期待摊费用摊销11,314,041.8-5,469,673.24-
处置固定资产、无形资产和其他长期资产的损失-78,661.39--122,811.82-
固定资产报废损失5,709,620.93-2,034,397.69-
公允价值变动损失-32,940,014.29--19,356,426.44-
财务费用13,124,519.99-8,372,221.48-
投资损失-137,517,910.98--67,879,421.27-
递延所得税3,707,251.35--2,746,010.84-
其中:递延所得税资产减少6,385,601.46--741,284.77-
递延所得税负债增加-2,678,350.11--2,004,726.07-
存货的减少-416,884,677.76--248,989,496.05-
经营性应收项目的减少840,461,407.42-412,483,525.59-
经营性应付项目的增加-723,825,743.11--328,732,690.81-
其他11,084,642.93-23,981,670.54-
现金的期末余额1,358,260,221.68-2,025,760,219.96-
减:现金的期初余额989,324,615.51-989,324,615.51-
公告日期2025-03-292024-10-302024-08-302024-04-26
审计意见(境内)标准无保留意见
TOP↑